Get started
Author

Aoi Morishita

Observed name: Aoi MORISHITA
ORCID: 0009-0001-2528-1852
Observed ORCID: 0009-0001-2528-1852
OpenAlex ID: A5065436094
First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors
2022 · Masatoshi Takagi, Chitose Ogawa, et al. · Cancer · 24
PDF
Successful ruxolitinib administration for a patient with steroid‐refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review
2021 · Dan Tomomasa, Takeshi Isoda, et al. · Clinical Case Reports · 12
PDF
Clinical Utility and Limitations of Ultrasound‐Guided Axillary Lymph Node Fine‐Needle Aspiration Cytology in Breast Cancer Management
2025 · Aoi Morishita, Tomoyuki Shimada · Diagnostic Cytopathology
PDF
De Novo Stage IV Breast Cancer with Durable Response Lasting for 17 Years to Endocrine Therapy Alone—A Case Report—
2025 · Aoi MORISHITA, Tomoyuki SHIMADA · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
PDF
Transient immune deficiency accompanied with homozygous CBL rare variant
2022 · Aoi Morishita, Tzu‐Wen Yeh, et al. · Pediatrics International
Works count: 5
Citation count: 36
H-index: 2
I10-index: 2
Year
Topic
Type